Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • trastuzumab deruxtecan

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

    In 2022, nearly one million new patients were diagnosed with gastric cancer

    - PMLiVE

    AstraZeneca announces $2bn investment in US manufacturing

    The new and expanded facilities will support production of rare disease drug treatments

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    AstraZeneca reports positive results from rare disease trial

    HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

    - PMLiVE

    AstraZeneca reports positive results from phase 3 blood pressure trial

    The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension

    - PMLiVE

    AstraZeneca to invest $4.5bn in US manufacturing facility

    The investment will further support the company’s growing oncology pipeline

    - PMLiVE

    AstraZeneca announces agreement with US government to reduce medicine costs

    The pharma company is the latest to offer direct-to-consumer purchasing

    - PMLiVE

    AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

    Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

    Innovative Trials

    - PMLiVE

    Lilly reports survival benefit with Verzenio in high-risk early breast cancer

    The findings are based on Lilly’s phase 3 monarchE trial

    - PMLiVE

    AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

    Approximately 6,600 people are diagnosed with liver cancer every year in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links